By Professor Richard Bryan Lock

Journal articles

Gorlick R; Maris JM; Houghton PJ; Lock RB; Carol H; Kurmasheva RT; Kolb EA; Reynolds CP; Kang MH; Billups CA; Smith MA, 2012, 'Testing of the Akt/PKB inhibitor MK-2206 by the pediatric preclinical testing program', Pediatric Blood and Cancer, 59, pp. 518 - 524, http://dx.doi.org/10.1002/pbc.23412

Houghton PJ; Lock RB; Carol H; Morton CL; Gorlick R; Kolb EA; Keir ST; Reynolds CP; Kang MH; Maris JM; Billups C; Zhang MX; Madden SL; Teicher BA; Smith MA, 2012, 'Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program', Pediatric Blood and Cancer, 58, pp. 200 - 209, http://dx.doi.org/10.1002/pbc.23016

Smith MPW; Wood SL; Zougman A; Ho JTC; Peng J; Jackson D; Cairns DA; Lewington AJP; Selby PJ; Banks RE, 2011, 'A systematic analysis of the effects of increasing degrees of serum immunodepletion in terms of depth of coverage and other key aspects in top-down and bottom-up proteomic analyses.', Proteomics, 11, pp. 2222 - 2235, http://dx.doi.org/10.1002/pmic.201100005

Carol H; Boehm I; Reynolds CP; Kang MH; Maris JM; Morton CL; Gorlick R; Kolb EA; Keir ST; Wu J; Wozniak AE; Yang Y; Manfredi M; Ecsedy J; Wang J; Neale G; Houghton PJ; Smith MA; Lock RB, 2011, 'Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer', Cancer Chemotherapy and Pharmacology, 68, pp. 1291 - 1304, http://dx.doi.org/10.1007/s00280-011-1618-8

Thoms JAI; Birger Y; Foster S; Knezevic K; Kirshenbaum Y; Chandrakanthan V; Jonquieres G; Spensberger D; Wong JW; Oram SH; Kinston SJ; Groner Y; Lock RB; MacKenzie KL; Gottgens B; Izraeli S; Pimanda JE, 2011, 'ERG promotes T-acute lymphoblastic leukemia and is transcriptionally regulated in leukemic cells by a stem cell enhancer', Blood, 117, pp. 7079 - 7089, http://dx.doi.org/10.1182/blood-2010-12-317990

Bhadri V; Cowley MJ; Kaplan W; Trahair TN; Lock RB, 2011, 'Evaluation of the NOD/SCID xenograft model for glucocorticoid-regulated gene expression in childhood B-cell precursor acute lymphoblastic leukemia', BMC Genomics, 12, pp. 1 - 13, http://dx.doi.org/10.1186/1471-2164-12-565

Kolb AE; Gorlick R; Lock RB; Carol H; Morton CL; Keir ST; Reynolds CP; Kang MH; Mans JM; Billups C; Smith MA; Houghton PJ, 2011, 'Initial Testing (Stage 1) of the IGF-1 Receptor Inhibitor BMS-754807 by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, 56, pp. 595 - 603, http://dx.doi.org/10.1002/pbc.22741

Smith MA; Maris JM; Lock RB; Kolb EA; Gorlick R; Keir ST; Carol H; Morton CL; Reynolds CP; Kang MH; Houghton PJ, 2011, 'Initial Testing (Stage 1) of the Polyamine Analog PG11047 by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, 57, pp. 268 - 274, http://dx.doi.org/10.1002/pmic.201100005

Reynolds CP; Kang MH; Keir ST; Gorlick R; Kolb EA; Lock RB; Maris JM; Carol H; Morton CL; Billups CA; Smith MA; Houghton PJ, 2011, 'Initial Testing of Lenalidomide by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, 57, pp. 606 - 611, http://dx.doi.org/10.1002/pbc.22877

Houghton PJ; Lock RB; Carol H; Morton CL; Phelps D; Gorlick R; Kolb EA; Keir ST; Reynolds CP; Kang MH; Maris JM; Wozniak AW; Gu Y; Wilson WR; Smith MA, 2011, 'Initial Testing of the Hypoxia-Activated Prodrug PR-104 by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, 57, pp. 443 - 453, http://dx.doi.org/10.1002/pbc.22921

Davies C; Hogarth L; Dietrich PA; Bachmann PS; Mackenzie KL; Hall AG; Lock RB, 2011, 'p53-independent epigenetic repression of the p21WAF1 gene in T-cell acute lymphoblastic leukemia', The Journal of Biological Chemistry, 286, pp. 37639 - 37650, http://dx.doi.org/10.1074/jbc.M111.272336

Benito J; Shi Y; Szymanska B; Carol H; Boehm I; Lu H; Konoplev S; Fang W; Zweidler-McKay PA; Campana D; Borthakur G; Bueso-ramos C; Shpall E; Thomas DA; Jordan CT; Kantarjian H; Wilson WR; Lock RB; Andreeff M; Konopleva M; Ingrid , 2011, 'Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104', PLoS ONE, 6, pp. e23108, http://dx.doi.org/10.1371/journal.pone.0023108

Barry JB; Lock RB, 2011, 'Small ubiquitin-related modifier-1: Wrestling with protein regulation', International Journal of Biochemistry and Cell Biology, 43, pp. 37 - 40, http://dx.doi.org/10.1016/j.biocel.2010.09.022

Lu H; Battula VL; Korchin B; Spong S; Canizales M; Lock RB; Andreeff M; Konopleva M, 2010, 'Targeting Connective Tissue Growth Factor (CTGF) In Acute Lymphoblastic Leukemia Pre-Clinical Models: Anti-CTGF Monoclonal Antibody Attenuates Tumor Growth In Mouse Models of ALL', Blood, 116, pp. 3257 - 3257, http://dx.doi.org/10.1182/blood.v116.21.3257.3257

Oram SH; Thoms JAI; Pridans C; Janes ME; Kinston SJ; Anand S; Landry JR; Lock RB; Jayaraman PS; Huntly BJ; Pimanda JE; Gottgens B, 2010, 'A previously unrecognized promoter of LMO2 forms part of a transcriptional regulatory circuit mediating LMO2 expression in a subset of T-acute lymphoblastic leukaemia patients', Oncogene, 29, pp. 5796 - 5808, http://dx.doi.org/10.1038/onc.2010.320

Bachmann PS; Piazza RG; Janes M; Wong NC; Davies C; Mogavero A; Bhadri V; Szymanska B; Geninson G; Magistroni V; Cazaniga G; Biondi A; Miranda-saavedra D; Gottgens B; Saffery R; Craig JM; Marshall GM; Gambacorti-passerini C; Pimanda JE; Lock RB, 2010, 'Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition', Blood, 116, pp. 3013 - 3022, http://dx.doi.org/10.1182/blood-2010-05-284968

Kolb EA; Gorlick R; Houghton PJ; Morton CL; Keir ST; Carol H; Lock RB; Phelps D; Kang MH; Reynolds CP; Maris JM; Billups C; Smith MA, 2010, 'Initial Testing (Stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, 55, pp. 668 - 677, http://dx.doi.org/10.1002/pbc.22576

Smith MA; Morton CL; Kolb EA; Gorlick R; Keir ST; Carol H; Lock RB; Kang MH; Reynolds CP; Maris JM; Watkins AE; Houghton PJ, 2010, 'Initial Testing (Stage 1) of Mapatumumab (HGS-ETR1) by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, 54, pp. 307 - 310, http://dx.doi.org/10.1002/pbc.22188

Carol H; Morton CL; Gorlick R; Kolb EA; Keir ST; Reynolds CP; Kang MH; Maris JM; Billups C; Smith MA; Houghton PJ; Lock RB, 2010, 'Initial Testing (Stage 1) of the Akt Inhibitor GSK690693 by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, 55, pp. 1329 - 1337, http://dx.doi.org/10.1002/pbc.22710

Keir ST; Maris JM; Lock RB; Kolb EA; Gorlick R; Carol H; Morton CL; Reynolds CP; Kang MH; Watkins A; Houghton PJ; Smith MA, 2010, 'Initial Testing (Stage 1) of the Multi-Targeted Kinase Inhibitor Sorafenib by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, 55, pp. 1126 - 1133, http://dx.doi.org/10.1002/pbc.22712

Maris JM; Morton CL; Gorlick R; Kolb EA; Lock RB; Carol H; Keir ST; Reynolds CP; Kang MH; Wu J; Smith MA; Houghton PJ, 2010, 'Initial Testing of the Aurora Kinase A Inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)', Pediatric Blood and Cancer, 55, pp. 26 - 34, http://dx.doi.org/10.1002/pbc.22430

Carol H; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Maris JM; Keir ST; Watkins A; Smith MA; Lock RB, 2010, 'Initial Testing of Topotecan by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, 54, pp. 707 - 715, http://dx.doi.org/10.1002/pbc.22352

Napier CE; Veas LA; Kan C; Taylor LM; Yuan J; Wen VW; James A; O'Brien TA; Lock RB; Mackenzie K, 2010, 'Mild hyperoxia limits hTR levels, telomerase activity, and telomere length maintenance in hTERT-transduced bone marrow endothelial cells', Biochimica et Biophysica ACTA - Molecular Cell Research, 1803, pp. 1142 - 1153, http://dx.doi.org/10.1016/j.bbamcr.2010.06.010

Houghton PJ; Morton CL; Gorlick R; Lock RB; Carol H; Reynolds CP; Kang MH; Maris JM; Keir ST; Kolb EA; Wu J; Wozniak AW; Billups CA; Rubinstein L; Smith MA, 2010, 'Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program', Molecular Cancer Therapeutics, 9, pp. 101 - 112, http://dx.doi.org/10.1158/1535-7163.MCT-09-0952

High L; Szymanska B; Wilczynska-kalak U; Barber N; O'Brien R; Khaw SL; Vikstrom IB; Roberts AW; Lock RB; High L, 2010, 'The Bcl-2 Homology Domain 3 Mimetic ABT-737 Targets the Apoptotic Machinery in Acute Lymphoblastic Leukemia Resulting in Synergistic in Vitro and in Vivo Interactions with Established Drugs', Molecular Pharmacology, 77, pp. 483 - 494, http://dx.doi.org/10.1124/mol.109.060780

Samuels AL; Peeva VK; Papa R; Firth MJ; Francis RW; Beesley AH; Lock RB; Kees UR, 2010, 'Validation of a mouse xenograft model system for gene expression analysis of human acute lymphoblastic leukaemia', BMC Genomics, 11, pp. 256, http://dx.doi.org/10.1186/1471-2164-11-256

Gorlick R; Kolb EA; Houghton PJ; Morton CL; Phelps D; Schaiquevich P; Stewart C; Keir ST; Lock RB; Reynolds CP; Maris JM; Wu J; Smith MA, 2009, 'Initial Testing (Stage 1) of Lapatinib by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, 53, pp. 594 - 598, http://dx.doi.org/10.1002/pbc.21989

Carol H; Lock RB; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA, 2009, 'Initial Testing (Stage 1) of the Kinesin Spindle Protein Inhibitor Ispinesib by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, 53, pp. 1255 - 1263, http://dx.doi.org/10.1002/pbc.22056

Keshelava N; Houghton PJ; Morton CL; Lock RB; Carol H; Keir ST; Maris JM; Reynolds CP; Gorlick R; Kolb EA; Wu J; Smith MA, 2009, 'Initial Testing (Stage 1) of Vorinostat (SAHA) by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, 53, pp. 505 - 508, http://dx.doi.org/10.1002/pbc.21988

Morton CL; Houghton PJ; Gorlick R; Kolb EA; Lock RB; Carol H; Keir ST; Reynolds CP; Kang MH; Maris JM; Billups C; Smith MA, 2009, 'Initial Testing of Aplidin by the Pediatric Pre-Clinical Testing Program', Pediatric Blood and Cancer, 53, pp. 509 - 512, http://dx.doi.org/10.1002/pbc.21976

Kang MH; Harutyunyan N; Hall CP; Papa R; Lock RB, 2009, 'Methotrexate and aminopterin exhibit similar in vitro and in vivo preclinical activity against acute lymphoblastic leukaemia and lymphoma', British Journal of Haematology, 145, pp. 389 - 393, http://dx.doi.org/10.1111/j.1365-2141.2009.07631.x

Jin L; Lee EM; Ramshaw HS; Busfield SJ; Peoppl AG; Wilkinson L; Guthridge M; Thomas D; Barry EF; Boyd A; Gearing DP; Vairo G; Lopez AF; Dick J; Lock RB, 2009, 'Monoclonal Antibody-Mediated Targeting of CD123, IL-3 Receptor alpha Chain, Eliminates Human Acute Myeloid Leukemic Stem Cells', Cell Stem Cell, 5, pp. 31 - 42, http://dx.doi.org/10.1016/j.stem.2009.04.018

Lee EM; Lock RB, 2009, 'Targeting of AML-leukemic stem cells with monoclonal antibodies', Future Oncology, 5, pp. 1327 - 1330, http://dx.doi.org/10.2217/FON.09.115

Yuan J; Yang BMP; Zhong Z; Shats I; Milyavsky M; Rotter V; Lock RB; Reddel R; Mackenzie K, 2009, 'Upregulation of survivin during immortalization of nontransformed human fibroblasts transduced with telomerase reverse transcriptase', Oncogene, 28, pp. 2678 - 2689, http://dx.doi.org/10.1038/onc.2009.136

Ong V; Liem N; Schmid M; Verrills NM; Papa R; Marshall GM; Mackenzie K; Kavallaris M; Lock RB, 2008, 'A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia xenografts', Journal of Pharmacology and Experimental Therapeutics, 324, pp. 434 - 442, http://dx.doi.org/10.1124/jpet.107.128926

Henderson M; Choi S; Beesley A; Baker DL; Wright DC; Papa R; Murch A; Campbell L; Lock RB; Norris MD; Haber M; Kees UR, 2008, 'A xenograft model of infant leukaemia reveals a complex MLL translocation', British Journal of Haematology, 140, pp. 716 - 719, http://dx.doi.org/10.1111/j.1365-2141.2007.06966.x

Kolb EA; Gorlick R; Houghton P; Morton C; Lock RB; Carol H; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA, 2008, 'Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the Pediatric Preclinical Testing Program.', Pediatric Blood and Cancer, 50, pp. 1190 - 1197

Maris JM; Courtright J; Houghton P; Morton C; Kolb EA; Lock RB; Tajbakhsh M; Reynolds CP; Keir ST; Wu J; Smith MA, 2008, 'Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program.', Pediatric Blood and Cancer, 51, pp. 42 - 48, http://dx.doi.org/10.1002/pbc.21535

Lock RB; Carol H; Houghton P; Morton CR; Kolb EA; Gorlick R; Reynolds CP; Maris JM; Keir ST; Wu JJ; Smith MS, 2008, 'Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program', Pediatric Blood and Cancer, 50, pp. 1181 - 1189, http://dx.doi.org/10.1002/pbc.21433

Houghton P; Morton C; Kolb EA; Gorlick R; Lock RB; Carol H; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA, 2008, 'Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program.', Pediatric Blood and Cancer, 50, pp. 799 - 805

Houghton P; Morton C; Kolb EA; Lock RB; Carol H; Reynolds CP; Keshelava N; Maris JM; Keir ST; Wu J; Smith MA, 2008, 'Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program', Pediatric Blood and Cancer, 50, pp. 37 - 45

Tajbakhsh M; Houghton P; Morton CL; Kolb A; Gorlick R; Maris JM; Keir ST; Wu J; Reynolds CP; Smith MA; Lock RB, 2008, 'Initial testing of Cisplatin by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, 50, pp. 992 - 1000

Kolb A; Gorlick R; Houghton P; Morton C; Lock RB; Tajbakhsh M; Maris JM; Reynolds CP; Keir ST; Billups CA; Smith MA, 2008, 'Initial testing of dasatinib by the Pediatric Preclinical Testing Program.', Pediatric Blood and Cancer, 50, pp. 1198 - 1206

Maris JM; Courtright J; Houghton P; Morton C; Gorlick R; Kolb EA; Lock RB; Tajbakhsh M; Reynolds CP; Keir ST; Wu J; Smith MA, 2008, 'Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program.', Pediatric Blood and Cancer, 50, pp. 581 - 587

Dilda P; Perrone G; Philp A; Lock RB; Dawes IW; Hogg PJ, 2008, 'Insight into the selectivity of arsenic trioxide for acute promyelocytic leukemia cells by characterizing Saccharomyces cerevisiae deletion strains that are sensitive or resistant to the metalloid', International Journal of Biochemistry and Cell Biology, 40, pp. 1016 - 1029, http://dx.doi.org/10.1016/j.biocel.2007.11.002

Lock RB; Neale G; Su X; Morton CL; Phelps D; Gorlick R; Reynolds CP; Maris JM; Friedman HSEA, 2008, 'Molecular characterization of the pediatric preclinical testing panel', Clin Cancer Res, 14, pp. 4572 - 4583

Brands K; Colvin EK; Williams LJ; Wang R; Lock RB; Tuch BE, 2008, 'Reduced immunogenicity of first-trimester human fetal pancreas.', Diabetes, 57, pp. 627 - 634, http://dx.doi.org/10.2337/db07-0720a

Choo A; Palladinetti P; Holmes TA; Basu S; Shen S; Lock RB; O Brien T; Symonds GP; Dolnikov A, 2008, 'siRNA targeting the IRF2 transcription factor inhibits leukaemic cell growth.', International Journal of Oncology, 33, pp. 175 - 183

Smith MA; Morton CL; Phelps DA; Kolb EA; Lock RB; Carol H; Reynolds CP; Maris JM; Keir ST; Wu J; Houghton PJ, 2008, 'Stage 1 Testing and Pharmacodynamic Evaluation of the HSP90 Inhibitor Alvespimycin (17-DMAG, KOS-1022) by the Pediatric Preclinical Testing Program', Pediatric Blood and Cancer, 51, pp. 34 - 41

Markovic A; Mackenzie KL; Lock RB, 2007, 'Induction of vascular endothelial growth factor secretion in acute leukemia cells via the FLT-3 signaling pathway', MOLECULAR CANCER THERAPEUTICS, 6, pp. 3344S - 3344S, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000251969000042&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Back to profile page